Eventide Asset Management Has Lowered Abbvie (ABBV) Holding By $10.32 Million; CANEXUS CORPORATION (TSE:CUS) Covered By 1 Bullish Analysts Last Week

April 22, 2018 - By Vivian Park

AbbVie Inc. (NYSE:ABBV) Logo

Among 4 analysts covering Canexus Corporation (TSE:CUS), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Canexus Corporation had 12 analyst reports since September 3, 2015 according to SRatingsIntel. On Thursday, September 1 the stock rating was maintained by Scotia Capital with “Sector Perform”. The firm has “Tender” rating by Scotia Capital given on Monday, January 30. The firm earned “Outperform” rating on Monday, November 2 by Raymond James. The stock of CANEXUS CORPORATION (TSE:CUS) has “Sector Perform” rating given on Wednesday, July 6 by IBC. The firm has “Sector Perform” rating given on Thursday, September 15 by RBC Capital Markets. The firm has “Tender” rating given on Friday, December 16 by National Bank Canada. See CANEXUS CORPORATION (TSE:CUS) latest ratings:

Eventide Asset Management Llc decreased Abbvie Inc (ABBV) stake by 19.39% reported in 2017Q4 SEC filing. Eventide Asset Management Llc sold 107,500 shares as Abbvie Inc (ABBV)’s stock declined 6.31%. The Eventide Asset Management Llc holds 447,000 shares with $43.23 million value, down from 554,500 last quarter. Abbvie Inc now has $146.93B valuation. The stock decreased 0.44% or $0.41 during the last trading session, reaching $92.6. About 4.75M shares traded. AbbVie Inc. (NYSE:ABBV) has risen 39.20% since April 22, 2017 and is uptrending. It has outperformed by 27.65% the S&P500.

The stock decreased 0.61% or $0.01 during the last trading session, reaching $1.64. About 13,270 shares traded or Infinity% up from the average. CANEXUS CORPORATION (TSE:CUS) has 0.00% since April 22, 2017 and is . It has underperformed by 11.55% the S&P500.

Eventide Asset Management Llc increased Voyager Therapeutics Inc stake by 142,000 shares to 703,425 valued at $11.68M in 2017Q4. It also upped Biohaven Pharmactl Hldg Co L stake by 188,760 shares and now owns 242,000 shares. Protagonist Therapeutics Inc was raised too.

Among 23 analysts covering Abbvie Inc (NYSE:ABBV), 10 have Buy rating, 2 Sell and 11 Hold. Therefore 43% are positive. Abbvie Inc had 89 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by UBS on Friday, October 23 with “Buy”. Goldman Sachs maintained AbbVie Inc. (NYSE:ABBV) on Friday, March 10 with “Buy” rating. Cowen & Co upgraded the shares of ABBV in report on Wednesday, October 11 to “Outperform” rating. The stock of AbbVie Inc. (NYSE:ABBV) earned “Buy” rating by Piper Jaffray on Friday, September 15. The firm has “Sell” rating by Societe Generale given on Wednesday, April 6. The firm earned “Hold” rating on Thursday, March 22 by Leerink Swann. The firm earned “Buy” rating on Thursday, March 22 by SunTrust. The stock of AbbVie Inc. (NYSE:ABBV) has “Equal-Weight” rating given on Tuesday, December 1 by Barclays Capital. The firm earned “Buy” rating on Wednesday, July 22 by SunTrust. Credit Suisse maintained AbbVie Inc. (NYSE:ABBV) on Wednesday, June 7 with “Hold” rating.

Since October 30, 2017, it had 0 insider purchases, and 12 selling transactions for $49.35 million activity. Gosebruch Henry O also sold $1.66M worth of AbbVie Inc. (NYSE:ABBV) on Monday, October 30. $157,458 worth of AbbVie Inc. (NYSE:ABBV) was sold by SALEKI-GERHARDT AZITA on Wednesday, February 28. Another trade for 25,000 shares valued at $2.95M was sold by Schumacher Laura J. 87,040 shares valued at $8.57M were sold by RICHMOND TIMOTHY J. on Monday, December 18. GONZALEZ RICHARD A also sold $976,084 worth of AbbVie Inc. (NYSE:ABBV) shares. On Monday, February 19 Michael Robert A. sold $119,351 worth of AbbVie Inc. (NYSE:ABBV) or 992 shares. $311,684 worth of AbbVie Inc. (NYSE:ABBV) was sold by SEVERINO MICHAEL on Wednesday, February 28.

Analysts await AbbVie Inc. (NYSE:ABBV) to report earnings on April, 26 before the open. They expect $1.78 earnings per share, up 39.06% or $0.50 from last year’s $1.28 per share. ABBV’s profit will be $2.82 billion for 13.01 P/E if the $1.78 EPS becomes a reality. After $1.48 actual earnings per share reported by AbbVie Inc. for the previous quarter, Wall Street now forecasts 20.27% EPS growth.

AbbVie Inc. (NYSE:ABBV) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: